TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly ...

Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational ...

in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination ...

Highlights of the ASH poster presentation: TUS as Single Agent (n= 93 Patients) 60% and 42% CR/CRh with 80 mg TUS in FLT3 mutated and all-comer VEN-naïve AML 33% CRc & 42% ORR (CR, CRp ...

in a poster presentation at the 66 th American Society of Hematology (ASH) Annual Meeting in San Diego. Tuspetinib (TUS), being developed by Aptose and originally created by Hanmi Pharmaceutical Co., ...

in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations at the American Society of Hematology Annual ...

2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced that an abstract has been selected for presentation at the 66 th Annual ASH Annual Meeting and Exposition, being held in San ...

Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with myelodysplastic syndromes ...